Clinical trials
Resistant Cancer clinical trials
Below are recruiting resistant cancer clinical trials, each written for real people, not researchers. We’re tracking 403 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07112209Enrolling by invitation
Rezvilutamide plus chemo for prostate cancer
This study tests a new combination treatment (Rezvilutamide plus docetaxel chemotherapy) for men with advanced prostate cancer that has stopped responding to abiraterone. The goal is to see if this combination can help control the cancer.
Guangzhou, GuangdongAges 18 years+ - NCT05753826RecruitingPhase 2
Study of two medicines for platinum-resistant ovarian cancer
This Phase 2 trial studies whether adding adebrelimab to fuzuloparib can help people with ovarian cancer that comes back quickly after platinum chemotherapy. It is aimed especially at tumors with a specific DNA-repair gene (HRR mutation).
FujianAges 18–70 - NCT07666555RecruitingPhase 2
Culmerciclib rechallenge for HR+ HER2- breast cancer
This trial tests a new drug called Culmerciclib for women with advanced HR-positive, HER2-negative breast cancer that has stopped responding to a CDK4/6 inhibitor with hormone therapy. The goal is to see if giving this drug again can help when other treatments no longer work.
ShanghaiAges 18–75 - NCT05452213RecruitingPhase 4
Study patterns of ribociclib response and resistance in breast cancer
This trial looks at how well ribociclib works and why it may stop working over time in people with advanced, hormone-receptor–positive, HER2-negative breast cancer. It also analyzes blood and tissue samples to help researchers understand resistance patterns and improve future treatment decisions.
Erlangen, BavariaAges 18 years+ - NCT06216249RecruitingPhase 2
Flexible dosing of Lu-PSMA for advanced prostate cancer
This trial tests a flexible dosing schedule of a targeted radiation drug (Lu-PSMA) for men with metastatic prostate cancer that has stopped responding to hormone therapy and chemotherapy. It aims to see if adjusting the treatment schedule can improve outcomes while reducing side effects.
Los Angeles, CaliforniaAges 18 years+ - NCT06586957RecruitingPhase 1
Study of NKT3964 for advanced solid tumors
This trial is testing an experimental oral drug called NKT3964 for people with advanced solid tumors that have stopped responding to standard treatments. The drug works by blocking a protein called CDK2, which some cancers need to grow.
Little Rock, ArkansasAges 18 years+ - NCT05636605Recruiting
Study lung cancer biology and why immunotherapy stops working
This study looks at lung cancer tissue and immune system changes to understand how and why immunotherapy resistance develops. It may help researchers find better ways to make immunotherapy work longer for future patients.
Yiwu, ZhejiangAges 18–80 - NCT05976815Recruiting
Exercise added to chemotherapy before breast cancer surgery
This study tests whether adding a supervised physical exercise program around the time of “before-surgery” chemotherapy helps people with newly diagnosed breast cancer. You may be assigned to an exercise group or a usual-care group, and the researchers will compare outcomes between them.
Vila Nova de Gaia, Porto DistrictAges 18 years+ - NCT06193486RecruitingPhase 1
T-Cell Therapy for Advanced Prostate Cancer with Bone Spread
This trial tests a new type of immune cell therapy (gamma delta T cells) targeted at a marker on prostate cancer cells to see if it can shrink bone metastases in advanced, castration-resistant prostate cancer. It’s for men who have already tried chemotherapy and newer hormone therapies and whose cancer is getting worse.
Tampa, FloridaAges 18 years+ - NCT06978296Recruiting
HIMARS: Stereotactic radiation for prostate cancer spread
This trial tests adding targeted radiation (SRT) to bone or lymph node metastases in men with prostate cancer that has continued to grow despite hormone therapy, chemo, or other treatments. The goal is to see if radiation can help control the disease and improve outcomes.
Saint-HerblainAges 18 years+ - NCT06126731RecruitingPhase 1/Phase 2
Antibiotics plus enzalutamide for advanced prostate cancer
This trial tests whether adding specific antibiotics (amoxicillin, metronidazole, vancomycin, ciprofloxacin) to enzalutamide can help treat advanced prostate cancer that has stopped responding to other treatments. It aims to see if changing gut bacteria can make the cancer therapy work better.
BellinzonaAges 18 years+ - NCT07142551RecruitingPhase 2
Testosterone priming with darolutamide for metastatic prostate cancer
This trial tests whether giving a high dose of testosterone before standard hormone therapy can help the treatment work longer for men with prostate cancer that has spread. You would receive testosterone injections for a short time, then a hormone blocker (darolutamide) along with continued testosterone shots.
Baltimore, MarylandAges 18 years+ - NCT05176483RecruitingPhase 1
New drug combinations for advanced solid tumors
This trial tests a new drug called zanzalintinib, which may slow or shrink various types of advanced cancer. It is given together with other cancer treatments, and the study is looking at many different cancers including kidney, prostate, bladder, lung, liver, and more.
Phoenix, ArizonaAges 18 years+ - NCT06922318RecruitingPhase 2
Combined suppression of MYC for advanced prostate cancer
This trial tests a new combination of drugs (ZEN-3694 and enzalutamide) for men with advanced prostate cancer that has stopped responding to standard hormonal treatments. It aims to see if this combination can help slow or stop the cancer from growing.
Baltimore, MarylandAges 18 years+ - NCT06343038RecruitingPhase 1
A new targeted radiation drug for advanced prostate cancer
This trial tests a new radioactive drug (161Tb-SibuDAB) for men with metastatic prostate cancer that has grown despite standard treatments. It aims to find the right dose and see if it can shrink tumors.
BaselAges 18 years+ - NCT07476001RecruitingPhase 2
High-dose testosterone and PSMA-targeted radiation for prostate cancer
This trial tests whether a short course of high-dose testosterone followed by a radioactive drug (PSMA-617) can help men with advanced prostate cancer that has stopped responding to hormone therapy. The goal is to make cancer cells more sensitive to the radiation.
Tampa, FloridaAges 18 years+ - NCT06199895RecruitingPhase 2
Study of paclitaxel for patients with taxane-resistant solid tumors
This trial tests paclitaxel given as tiny micelle particles for people whose cancer (pancreatic, bile duct, lung, stomach, esophagus, or breast) stopped responding to taxane chemotherapy or did not shrink. The goal is to see if this treatment can help when standard taxanes no longer work.
Wuhan, HubeiAges 18 years+ - NCT07549256RecruitingPhase 2
Cannabidiol for Pain Relief in Advanced Prostate Cancer
This trial tests whether cannabidiol (CBD), a non-intoxicating cannabis compound, can help relieve pain in patients with advanced prostate cancer that has stopped responding to standard treatments. You would take CBD daily alongside your current morphine pain medication.
GistrupAges Any age - NCT06241846RecruitingPhase 2
Study of YL201 for advanced prostate cancer that has spread and stopped responding to hormone therapy
This trial tests a new drug, YL201, in men with advanced prostate cancer that has spread and is no longer controlled by standard hormone therapy. The goal is to see if YL201 can shrink tumors or slow the cancer's growth.
Hefei, AnhuiAges 18 years+ - NCT06031805Recruiting
Real-world study of olaparib for prostate cancer
This study looks at how men with advanced prostate cancer that has spread are doing while taking the drug olaparib. Researchers want to understand how well the drug works and what happens to patients over time.
AmiensAges 18 years+ - NCT03851640RecruitingPhase 3
Study drug for advanced prostate cancer that kept spreading despite standard treatments
This Phase 3 study tests HC-1119 soft capsules in men with metastatic castration-resistant prostate cancer—cancer that keeps progressing even when testosterone is blocked. It aims to see whether the drug works better than expected and is safe, especially after prior treatments like abiraterone and/or docetaxel.
ShanghaiAges 18 years+ - NCT03522064RecruitingPhase 2
HRD-positive advanced prostate cancer trial with androgen therapy and chemo
This Phase 2 study tests whether blocking male hormones (androgen therapy) plus the chemotherapy drug carboplatin can shrink advanced prostate cancer in men with specific DNA repair problems. It is for cases where prostate-specific antigen (PSA) is rising even though testosterone is already kept very low.
Sydney, New South WalesAges 18 years+ - NCT06529549Recruiting
Organoid drug test for advanced prostate cancer
This trial uses a lab test on a tiny sample of your tumor (called an organoid) to find which drug might work best for your advanced prostate cancer. It's for men whose cancer has stopped responding to hormone therapy and got worse after first treatment.
Guangzhou, GuangdongAges 18–75 - NCT05116579Recruiting
Using blood DNA tests to track PARP inhibitor response
This trial uses a blood test (circulating tumor DNA) to see whether PARP inhibitors are working for certain men with advanced prostate cancer. It may help predict which treatment responses are likely and monitor changes over time.
Guangzhou, GuangdongAges 18–75
Hear when a new Resistant Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for resistant cancer?
- Yes. Clin2 currently lists 403 recruiting resistant cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a resistant cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a resistant cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Metastatic Castration-resistant Prostate Cancer
- Breast Cancer Early Stage Breast Cancer (Stage 1-3)
- Non Small Cell Lung Cancer
- Castration-resistant Prostate Cancer
- Platinum-resistant Ovarian Cancer
- Castrate Resistant Prostate Cancer
- Gastric Cancer, Gastroesophageal Junction Cancer
- Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.